RESONANCE HEALTH LIMITED
ACN 006 762 492
ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING

Resonance Health Limited (ACN 006 762 492) (**Company**) gives notice to Shareholders that, in relation to the Notice of Annual General Meeting dated 14 October 2026 (**Notice**) in respect of the Company's annual general meeting of members to be held at 10:00am (AWST) on Thursday, 19 November 2026 (**Meeting**), the Directors have resolved to include two new Resolutions, being Resolutions 9 and 10, within the Notice (**Additional Resolutions**), an additional Section 10 within the Explanatory Statement and additional defined terms within the Glossary as set out in this addendum (**Addendum**).

Capitalised terms in this Addendum have the same meaning as given in the Notice except as otherwise defined.

This Addendum is supplemental to the Notice and should be read in conjunction with the Notice. Apart from the amendments set out below, all Resolutions and the Explanatory Statement in the original Notice remain unchanged.

Replacement Proxy Form

Annexed to this Addendum to the Notice is a replacement Proxy Form (**Replacement Proxy Form**). To ensure clarity of voting instructions by Shareholders on the Resolutions to be considered at the Meeting, Shareholders are advised that:

(a) If you have already completed and returned the Proxy Form annexed with the Notice (**Original Proxy Form**) and you wish to change your original vote for Resolutions 1 to 8 or cast votes for the Additional Resolutions, **you must complete and return the Replacement Proxy Form**.

(b) If you have already completed and returned the Original Proxy Form and **you do not wish to change your original vote for Resolutions 1 to 8 or vote on the Additional Resolutions, you do not need to take any action** as the earlier submitted Original Proxy Form will be accepted by the Company for Resolutions 1 to 8 unless you submit a Replacement Proxy Form. For the sake of clarity, the Company notes that if you do not lodge a Replacement Proxy Form, **you will not have cast a vote on the Additional Resolutions.**

(c) If you have not yet completed and returned a Proxy Form and you wish to vote on the Resolutions in the Notice as supplemented by the Addendum, **please complete and return the Replacement Proxy Form.**

Replacement Proxy Forms must be received by no later than 10:00am (AWST) on Tuesday, 17 November 2026, in accordance with the instructions set out on the Replacement Proxy Form.

Enquiries

Should you wish to discuss the matters in this Addendum please do not hesitate to contact the Company Secretary on +61 8 9286 5300 or mitchellw@resonancehealth.com.

SUPPLEMENTARY BUSINESS OF THE MEETING

The agenda of the Notice is amended by including the following Resolutions:

9. RESOLUTION 9 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 35,621,296 Shares on the terms and conditions set out in the Explanatory Statement."

10. RESOLUTION 10 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1A

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 47,712,023 Shares on the terms and conditions set out in the Explanatory Statement."

Dated: 6 November 2026

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolutions set out below by or on behalf of the following persons:

Resolution 9 – Ratification of prior issue of Placement Shares – Listing Rule 7.1	A person who participated in the issue of the Placement Shares or an associate of that person or those persons.
Resolution 10 – Ratification of prior issue of Placement Shares – Listing Rule 7.1A	A person who participated in the issue of the Placement Shares or an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolutions by:

(a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

(b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

  (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and

  (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

SUPPLEMENTARY EXPLANATORY STATEMENT

The Explanatory Statement is supplemented by including the following Section:

10. RESOLUTIONS 9 AND 10 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES

10.1 General

On 27 October 2026, the Company announced that it had received firm commitments from institutional, professional and sophisticated investors for a placement of 83,333,319 Shares (**Placement Shares**) at an issue price of $0.072 per Share to raise approximately $6,000,000 (before costs) (**Placement**). No options or other Securities will be issued with the Placement Shares.

Bell Potter Securities Limited (**Bell Potter**) acted as lead manager to the Placement. The Company will pay Bell Potter a management fee of 2% and a selling fee of 3% of the gross proceeds of the Placement (being approximately $300,000 in aggregate, exclusive of GST) and reimburse Bell Potter for its reasonable out-of-pocket expenses incurred in connection with the Placement (including legal fees of up to $40,000). The Company has also granted Bell Potter a right of first refusal to act as lead manager to any equity capital raising (placement, rights issue and/or security purchase plan) undertaken by the Company within 12 months following completion of the Placement. The engagement was otherwise on standard terms for an agreement of its type.

The Placement Shares are expected to be issued on or about 9 November 2026 (being prior to the date of the Meeting) as follows:

(a) 35,621,296 Placement Shares pursuant to the Company's placement capacity under Listing Rule 7.1 (being the subject of Resolution 9); and

(b) 47,712,023 Placement Shares pursuant to the Company's placement capacity under Listing Rule 7.1A (being the subject of Resolution 10).

The Company intends to apply the funds raised under the Placement towards its three growth programmes (being MRI endpoint acceleration, the expansion of its TrialsWest east coast network and the development of its non-invasive liver fibrosis device), working capital and the costs of the Placement.

10.2 Listing Rules 7.1 and 7.1A

A summary of Listing Rule 7.1 is set out in Section 6.1.

Under Listing Rule 7.1A, however, an Eligible Entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%. The Company obtained this approval at its annual general meeting held on 13 November 2025. The Company is seeking to renew this approval under Resolution 5.

The issue of the Placement Shares does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 25% limit in Listing Rules 7.1 and 7.1A, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rules 7.1 and 7.1A for the 12 month period following the date of the issue.

10.3 Listing Rule 7.4

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the Placement Shares.

10.4 Technical information required by Listing Rule 14.1A

If Resolutions 9 and 10 are passed, the Placement Shares will be excluded in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of issue of the Placement Shares.

If Resolutions 9 and 10 are not passed, the Placement Shares will be included in calculating the Company's combined 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of issue of the Placement Shares.

If only one of Resolutions 9 and 10 is passed, only the Placement Shares the subject of that Resolution will be excluded from the calculation of the Company's combined 25% limit in Listing Rules 7.1 and 7.1A.

The Company's ability to utilise the additional 10% capacity provided for in Listing Rule 7.1A following the Meeting remains conditional on Resolution 5 being passed at the Meeting.

10.5 Technical information required by Listing Rules 7.4 and 7.5

REQUIRED INFORMATION	DETAILS
Names of persons to whom Securities were issued or the basis on which those persons were identified/selected	Professional and sophisticated investors who were identified through a bookbuild process, which involved Bell Potter seeking expressions of interest to participate in the Placement from non-related parties of the Company. The Company confirms that no Material Persons were or will be issued more than 1% of the issued capital of the Company under the Placement.
Number and class of Securities issued	83,333,319 Shares will be issued on the following basis: (a) 35,621,296 Shares pursuant to Listing Rule 7.1 (ratification of which is sought under Resolution 9); and (b) 47,712,023 Shares pursuant to Listing Rule 7.1A (ratification of which is sought under Resolution 10).
Terms of Securities	The Placement Shares are fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
Date(s) on or by which the Securities were issued	The Placement Shares are expected to be issued on or about 9 November 2026, being prior to the date of the Meeting.
Price or other consideration the Company received for the Securities	$0.072 per Placement Share issued pursuant to Listing Rule 7.1 and Listing Rule 7.1A.
Purpose of the issue, including the intended use of any funds raised by the issue	The purpose of the issue is to raise capital. Refer to Section 10.1 for details of the proposed use of funds.
Voting Exclusion Statement	A voting exclusion statement applies to each of Resolutions 9 and 10.
Compliance	The issue of the Placement Shares will not breach Listing Rule 7.1 or Listing Rule 7.1A.

SUPPLEMENTARY GLOSSARY

The Glossary is amended by inserting the following defined terms in the appropriate alphabetical order:

Addendum means the addendum to the Notice dated 6 November 2026.

Additional Resolutions has the meaning given in the Addendum.

Bell Potter has the meaning given in Section 10.1.

Material Person means a related party of the Company, a member of the Company's Key Management Personnel, a substantial holder of the Company, an adviser to the Company or an associate of any of those persons.

Original Proxy Form has the meaning given in the Addendum.

Placement has the meaning given in Section 10.1.

Placement Shares has the meaning given in Section 10.1.

Replacement Proxy Form has the meaning given in the Addendum.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Resonance Health Limited | ABN 96 006 762 492

Your proxy voting instruction must be received by **10:00am (AWST) on Tuesday, 17 November 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS
The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: **https://investor.automic.com.au/#/home** Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY
If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING
Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS
You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY
You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS
Individual: Where the holding is in one name, the Shareholder must sign.
Joint holding: Where the holding is in more than one name, all Shareholders should sign.
Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.
Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.
Email Address: Please provide your email address in the space provided.
By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES
If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at https://automicgroup.com.au.

Lodging your Proxy Voting Form:

Online
Use your computer or smartphone to appoint a proxy at https://portal.automic.com.au/investor/home or scan the QR code below using your smartphone
Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.

BY MAIL:
Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:
Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:
meetings@automicgroup.com.au

BY FACSIMILE:
+61 2 8583 3040

All enquiries to Automic:
WEBSITE:
https://automicgroup.com.au

PHONE:
1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

STEP 1 - How to vote

APPOINT A PROXY:

I/We being a Shareholder entitled to attend and vote at the Annual General Meeting of Resonance Health Limited, to be held at **10:00am (AWST) on Thursday, 19 November 2026 at QV1 Conference Centre, Level 2, 250 St Georges Terrace PERTH WA 6000** hereby:

Appoint the Chair of the Meeting (Chair) to vote in accordance with the following directions (or if no directions have been given, and subject to the relevant laws, as the Chair sees fit) at this meeting and at any adjournment thereof.

Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.

The Chair intends to vote undirected proxies in favour of all Resolutions in which the Chair is entitled to vote.
Unless indicated otherwise by marking the "for", "against" or "abstain" box you will be authorising the Chair to vote in accordance with the Chair's voting intention.

AUTHORITY FOR CHAIR TO VOTE UNDIRECTED PROXIES ON REMUNERATION RELATED RESOLUTIONS
Where I/we have appointed the Chair as my/our proxy (or where the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 1, 6 and 7 (except where I/we have indicated a different voting intention below) even though Resolutions 1, 6 and 7 are connected directly or indirectly with the remuneration of a member of the Key Management Personnel, which includes the Chair.

STEP 2 - Your voting direction

Resolutions		For	Against	Abstain
1	ADOPTION OF REMUNERATION REPORT	☐	☐	☐
2	ELECTION OF DIRECTOR – MR MICHAEL SISTENICH	☐	☐	☐
3	ELECTION OF DIRECTOR – DR DAVID FULLER	☐	☐	☐
4	RE-ELECTION OF DIRECTOR – DR TRAVIS BARONI	☐	☐	☐
5	APPROVAL OF 7.1A MANDATE	☐	☐	☐
6	APPROVAL TO ISSUE SECURITIES UNDER AN INCENTIVE PLAN	☐	☐	☐
7	ISSUE OF LOAN SHARES TO DIRECTOR – MR ANDREW HARRISON	☐	☐	☐
8	AMENDMENT TO CONSTITUTION	☐	☐	☐
9	RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1	☐	☐	☐
10	RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES – LISTING RULE 7.1A	☐	☐	☐

Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.

STEP 3 – Signatures and contact details

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name:

Email Address:

Contact Daytime Telephone

Date (DD/MM/YY) ☐☐ / ☐☐ / ☐☐

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

AUTOMIC

RHT